Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 328 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 328 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $40.09, for a total value of $13,149.52. Following the completion of the sale, the chief executive officer directly owned 38,872 shares in the company, valued at $1,558,378.48. This trade represents a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total transaction of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total transaction of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total transaction of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.02, for a total transaction of $232,425.60.
• On Monday, November 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.56, for a total transaction of $235,276.80.
• On Thursday, November 13th, Jack Bendheim sold 8,801 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.47, for a total transaction of $391,380.47.
• On Wednesday, November 12th, Jack Bendheim sold 21,536 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.23, for a total transaction of $974,073.28.
• On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The shares were sold at an average price of $45.29, for a total value of $1,734,742.87.

Phibro Animal Health Stock Up 0.7%

Shares of Phibro Animal Health stock traded up $0.29 on Thursday, reaching $39.72. The company’s stock had a trading volume of 153,681 shares, compared to its average volume of 196,536. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $46.42. The firm’s fifty day simple moving average is $40.89 and its two-hundred day simple moving average is $36.40. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of 23.93, a P/E/G ratio of 1.12 and a beta of 0.79.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The company had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were paid a $0.12 dividend. The ex-dividend date was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. Phibro Animal Health’s payout ratio is currently 28.92%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Phibro Animal Health in the 4th quarter worth $218,000. JPMorgan Chase & Co. lifted its position in Phibro Animal Health by 1,730.9% during the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after purchasing an additional 225,110 shares in the last quarter. Tudor Investment Corp ET AL grew its holdings in Phibro Animal Health by 3.4% during the third quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after purchasing an additional 338 shares during the period. Danske Bank A S bought a new stake in Phibro Animal Health during the third quarter valued at about $955,000. Finally, Advisory Services Network LLC purchased a new stake in Phibro Animal Health in the third quarter worth about $96,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on PAHC shares. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. JPMorgan Chase & Co. increased their price target on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $31.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.